Skip to content

Safety and Efficacy of Hs-cTnT Protocols

Safety and Efficacy of Hs-cTnT Protocols

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05484544
Enrollment
1167
Registered
2022-08-02
Start date
2013-02-01
Completion date
2014-04-30
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chest Pain, Diagnosis

Brief summary

Chest pain is a common presenting complaint among patients in the emergency department (ED). A large portion of patients with chest pain undergo lengthy assessment in the ED or are admitted to rule out acute oronary syndrome (ACS), often with stress testing, creating a substantial health care burden. The new high-sensitivity cardiac troponin assays allow use of shorter time intervals for repeated blood samples and may improve care for chest pain patients. The aim of this cohort is to evaluate high-sentivity troponin based protocols for ruling out and ruling in ACS in the ED.

Detailed description

This is a prospective observational study conducted at Skåne University Hospital (Lund, Sweden). Patients presenting with non-traumatic chest pain and for whom hs-cTnT testing was ordered at presentation will be enrolled between february 2013 to April 2014 after providing written informed consent. Patients with STEMI during index visit and those with severe communication barriers will not be enrolled. Enrolled patients will have a second blood sample for hs-cTnT analyzed 1 h after the first sample. Patients with hemolysis with a hemoglobin concentration \>0.1 g/dl, H-index \>=100 in either the 0- or 1-h sample will be excluded. Clinical data and 1-h high sensitivity troponin T samples will be collected by research assistants. Further diagnostic testing and treatment will be performed, as in routine care, at the discretion of the responsible physician.

Interventions

DIAGNOSTIC_TESTHigh sensitivity troponin T

Collection of hs-cTnT samples

Sponsors

Region Skane
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>=18 years of age * Presented to the ED with non-traumatic chest pain/discomfort * Hs-cTnT testing was ordered at presentation

Exclusion criteria

* STEMI at presentation * Severe communication barriers * Hemolysis with a hemoglobin concentration\>0.1 g/dl, H-index\>=100

Design outcomes

Primary

MeasureTime frameDescription
30-day MACE30 daysMACE within 30 days including the index visit. MACE was defined as an adjudicated diagnosis of AMI, UA, cardiac arrest, cardiogenic shock, ventricular arrhythmia requiring intervention, atrioventricular block requiring intervention, or death of a cardiac or unknown cause

Secondary

MeasureTime frameDescription
30-day MACE without UA30 daysDefined as an adjudicated diagnosis of AMI, cardiac arrest, cardiogenic shock, ventricular arrhythmia requiring intervention, atrioventricular block requiring intervention, or death of a cardiac or unknown cause

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026